Evidence map›Paper›PMID 42285356›Full record

ArticleSLAS discovery : advancing life sciences R & D2026

In silico prioritization and cheminformatics identify structurally diverse small-molecule inhibitors of Lassa virus glycoprotein-mediated membrane fusion.

Brianna J Close, Bruno La Rosa, Cameron Ong, Manu Anantpadma, Amr H Elkabbany, Sarah Hulsey Stubbs, Vincent Jo Davisson, Robert A Davey

Abstract read
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brianna J CloseDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine and National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA 02118, USA.
Bruno La RosaDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine and National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA 02118, USA.
Cameron OngDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine and National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA 02118, USA.
Manu AnantpadmaPfizer, 301 Middletown Road, Pearl River, NY 10965, USA.
Amr H ElkabbanyBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, USA; Department of Chemistry, Massachusetts College of Liberal Arts, North Adams, MA 01247, USA.
Sarah Hulsey StubbsDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine and National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA 02118, USA.
Vincent Jo DavissonBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University College of Pharmacy, West Lafayette, IN 47907, USA.
Robert A DaveyDepartment of Virology, Immunology and Microbiology, Chobanian & Avedisian School of Medicine and National Emerging Infectious Diseases Laboratories (NEIDL), Boston University, Boston, MA 02118, USA; National Emerging Infectious Diseases Laboratories, Boston University, MA 02118, USA. Electronic address: radavey@bu.edu.

Funding

Regulatory Compliance CoreUC7AI095321 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI ROBERT A DAVEY · 2014 to 2026
$159.3M
Project 5: Pandemic Virus Helicase InhibitorsU19AI171954 · NIAID · UNIVERSITY OF MINNESOTA · PI Reuben S Harris · 2022 to 2026
$100.9M
Antiviral Lead Identification to Treat Filovirus InfectionsR01AI128364 · NIAID · PURDUE UNIVERSITY · PI DAVEY, ROBERT A, DAVISSON, VINCENT JO · 2019 to 2022
$2.6M
NIAID NIH HHS R01 AI128364NIAID NIH HHS U19 AI171954NIAID NIH HHS UC7 AI095321
6 · The paper itself

Abstract

Lassa virus (LASV) is a hemorrhagic fever arenavirus of significant public health concern, infecting millions of people per year in Africa. Here, we developed a computational strategy to identify specific inhibitors of LASV glycoprotein-mediated virus cell entry, leveraging a previous screen of 297,156 small molecules from the MLPCN library, with the results deposited in the PubChem database. Data mining methods were developed to efficiently select small molecules prioritized for both potency and specificity in inhibiting Lassa virus infection. Cheminformatics classification then identified diverse chemical scaffolds that had not been previously reported. Representatives were evaluated against authentic LASV infection, yielding potencies as low as 10 nM. Investigation of the target mechanism compared vesicular stomatitis virus bearing the GPs of LASV, the distantly related Junín virus, and unrelated Ebola virus. The results identified three distinct chemical scaffolds that demonstrated strong LASV selectivity, each acting at the membrane fusion stage of virus cell entry. Sensitivity was mapped to regions of GP2 known to coordinate pH-triggered conformational rearrangements needed for membrane fusion. Time-of-addition experiments demonstrated loss of activity coincident with endosomal escape, and cell-cell fusion assays confirmed direct inhibition of GP-mediated syncytia formation. Together, these findings characterize each scaffold as an effective LASV fusion inhibitor and highlight the effectiveness of our combined computational and experimental approaches in identifying mechanistically informative antiviral scaffolds.

Indexed as

Antiviral AgentsCheminformaticsGlycoproteinsLassa virusMembrane FusionSmall Molecule LibrariesAnimalsComputer SimulationDrug DiscoveryHumansLassa FeverViral Envelope ProteinsVirus InternalizationAntiviral AgentsGlycoproteinsSmall Molecule LibrariesViral Envelope ProteinsAntiviralArenavirusCell entryCheminformaticsDrug discoveryHTSLassa virusMembrane fusion

Identifiers

PMID42285356
PMCPMC13567306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.